Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia

Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia Purpose of Review This article provides an overview of the current knowledge regarding the biology and treatment of Tcell acute lymphoblastic leukemia (T-ALL) and highlights the most recent findings in this field over the past 5 years. Recent Findings Remarkable progress has been made in the genomic landscape of T-ALL over the past few years. The discoveryofactivatingmutations of NOTCH1andFBXW7ina majority of patients has been a seminal observation, with several early phase clinical trials currently exploring these as potential therapeutic targets. Characterization of early T cell precursor ALL, incorporation of minimal residual disease assessment into therapeutic protocols, and use of pediatric- intensive regimens along with judicious use of allogeneic HCT have significantly improved risk stratification and treatment outcomes. Summary Improved risk stratification and the use of novel targeted therapies based on recent genomic discoveries are expected to change the therapeutic landscape of T-ALL and hopefully improve the outcomes of this historically poor prognosis disease. . . . Keywords Tcell acute lymphoblastic leukemia Early Tcell precursor acute lymphoblastic leukemia Minimal residual disease Nelarabine Targeted therapies Introduction from T-ALL somewhat arbitrarily by the presence of less than 20% marrow blasts [3, 4]. In this review, we will summarize T cell acute lymphoblastic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/recent-advances-in-the-biology-and-treatment-of-t-cell-acute-hp9UIO8Knv

References (80)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-018-0455-9
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review This article provides an overview of the current knowledge regarding the biology and treatment of Tcell acute lymphoblastic leukemia (T-ALL) and highlights the most recent findings in this field over the past 5 years. Recent Findings Remarkable progress has been made in the genomic landscape of T-ALL over the past few years. The discoveryofactivatingmutations of NOTCH1andFBXW7ina majority of patients has been a seminal observation, with several early phase clinical trials currently exploring these as potential therapeutic targets. Characterization of early T cell precursor ALL, incorporation of minimal residual disease assessment into therapeutic protocols, and use of pediatric- intensive regimens along with judicious use of allogeneic HCT have significantly improved risk stratification and treatment outcomes. Summary Improved risk stratification and the use of novel targeted therapies based on recent genomic discoveries are expected to change the therapeutic landscape of T-ALL and hopefully improve the outcomes of this historically poor prognosis disease. . . . Keywords Tcell acute lymphoblastic leukemia Early Tcell precursor acute lymphoblastic leukemia Minimal residual disease Nelarabine Targeted therapies Introduction from T-ALL somewhat arbitrarily by the presence of less than 20% marrow blasts [3, 4]. In this review, we will summarize T cell acute lymphoblastic

Journal

Current Hematologic Malignancy Reports – Springer Journals

Published: Jun 15, 2018

There are no references for this article.